EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Cytokeratin-18 is a sensitive biomarker of alanine transaminase increase in a placebo-controlled, randomized, crossover trial of therapeutic paracetamol dosing (PATH-BP biomarker substudy)

Kathleen M Scullion iD, Iain M MacIntyre, Sian Sloan-Dennison, Benjamin Clark, Paul Fineran, Joanne Mair, David Creasey, Cicely Rathmell, Karen Faulds, Duncan Graham, David J Webb iD, James W Dear

Toxicological Sciences · 2024

DOI: 10.1093/toxsci/kfae031 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Toxicological Sciences, 2024. Verfasst von Kathleen M Scullion und 11 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Cardiovascular Science, University of Edinburgh, Queen's Medical Research Institute, Edinburgh EH16 4TJ, UK. Hauptthemen laut MEDLINE: Acetaminophen, Cross-Over Studies, Alanine Transaminase, Biomarkers. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, PATH-BP trial study, British Heart Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug-induced liver injury (DILI) is a challenge in clinical medicine and drug development. Highly sensitive novel biomarkers have been identified for detecting DILI following a paracetamol overdose. The study objective was to evaluate biomarker performance in a 14-day trial of therapeutic dose paracetamol. The PATH-BP trial was a double-blind, placebo-controlled, crossover study. Individuals (n = 110) were randomized to receive 1 g paracetamol 4× daily or matched placebo for 2 weeks followed by a 2-week washout before crossing over to the alternate treatment. Blood was collected on days 0 (baseline), 4, 7, and 14 in both arms. Alanine transaminase (ALT) activity was measured in all patients. MicroRNA-122 (miR-122), cytokeratin-18 (K18), and glutamate dehydrogenase (GLDH) were measured in patients who had an elevated ALT on paracetamol treatment (≥50% from baseline). ALT increased in 49 individuals (45%). All 3 biomarkers were increased at the time of peak ALT (K18 paracetamol arm: 18.9 ± 9.7 ng/ml, placebo arm: 11.1 ± 5.4 ng/ml, ROC-AUC = 0.80, 95% CI 0.71–0.89; miR-122: 15.1 ± 12.9fM V 4.9 ± 4.7fM, ROC-AUC = 0.83, 0.75–0.91; and GLDH: 24.6 ± 31.1U/l V 12.0 ± 11.8U/l, ROC-AUC = 0.66, 0.49–0.83). All biomarkers were correlated with ALT (K18 r = 0.68, miR-122 r = 0.67, GLDH r = 0.60). To assess sensitivity, biomarker performance was analyzed on the visit preceding peak ALT (mean 3 days earlier). K18 identified the subsequent ALT increase (K18 ROC-AUC = 0.70, 0.59–0.80; miR-122 ROC-AUC = 0.60, 0.49–0.72, ALT ROC-AUC = 0.59, 0.48–0.70; GLDH ROC-AUC = 0.70, 0.50–0.90). Variability was lowest for ALT and K18. In conclusion, K18 was more sensitive than ALT, miR-122, or GLDH and has potential significant utility in the early identification of DILI in trials and clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcetaminophenCross-Over StudiesAlanine TransaminaseBiomarkersChemical and Drug Induced Liver InjuryKeratin-18HumansMaleFemaleDouble-Blind MethodAdultMiddle AgedMicroRNAsYoung AdultGlutamate DehydrogenaseAnalgesics, Non-Narcotic

Stichwörter der Autor:innen

DILIdiagnosisglutamate dehydrogenasekeratin-18livermicroRNA

Substanzen

AcetaminophenAlanine TransaminaseBiomarkersKeratin-18MIRN122 microRNA, humanKRT18 protein, humanMicroRNAsGlutamate DehydrogenaseAnalgesics, Non-Narcotic

Autor:innen und Institutionen

  • Centre for Cardiovascular Science, University of Edinburgh, Queen's Medical Research Institute, Edinburgh EH16 4TJ, UK.
  • Department of Pure and Applied Chemistry, Technology and Innovation Centre, University of Strathclyde, Glasgow G1 1RD, UK.
  • Centre for Inflammation Research, University of Edinburgh, Institute for Regeneration and Repair, Edinburgh EH16 4UU, UK.
  • Wasatch Photonics, Morrisville, North Carolina 27560, USA.
  • Centre for Precision Cell Therapy for the Liver, Lothian Health Board, Queen's Medical Research Institute, Edinburgh EH16 4TJ, UK.

ORCID-Profile: Kathleen M Scullion, David J Webb

Förderung

  • Medical Research Council
  • PATH-BP trial study
  • British Heart Foundation

Zitieren

APA

Scullion, K. M., MacIntyre, I. M., Sloan-Dennison, S., Clark, B., Fineran, P., Mair, J., Creasey, D., Rathmell, C., Faulds, K., Graham, D., Webb, D. J., & Dear, J. W. (2024). Cytokeratin-18 is a sensitive biomarker of alanine transaminase increase in a placebo-controlled, randomized, crossover trial of therapeutic paracetamol dosing (PATH-BP biomarker substudy). Toxicological Sciences. https://doi.org/10.1093/toxsci/kfae031

Vancouver

Scullion KM, MacIntyre IM, Sloan-Dennison S, Clark B, Fineran P, Mair J, et al. Cytokeratin-18 is a sensitive biomarker of alanine transaminase increase in a placebo-controlled, randomized, crossover trial of therapeutic paracetamol dosing (PATH-BP biomarker substudy). Toxicological Sciences. 2024. doi:10.1093/toxsci/kfae031

BibTeX
@article{Scullion2024,
  author = {Scullion, Kathleen M and MacIntyre, Iain M and Sloan-Dennison, Sian and Clark, Benjamin and Fineran, Paul and Mair, Joanne and Creasey, David and Rathmell, Cicely and Faulds, Karen and Graham, Duncan and Webb, David J and Dear, James W},
  title = {Cytokeratin-18 is a sensitive biomarker of alanine transaminase increase in a placebo-controlled, randomized, crossover trial of therapeutic paracetamol dosing (PATH-BP biomarker substudy)},
  journal = {Toxicological Sciences},
  year = {2024},
  doi = {10.1093/toxsci/kfae031}
}
Kostenlos starten →